• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Intuitive Surgical reports Street-beating Q1, shares lift 15% in after hours

Intuitive Surgical reports Street-beating Q1, shares lift 15% in after hours

April 19, 2016 By Fink Densford

Intuitive SurgicalIndustry-leading robotic surgery company Intuitive Surgical (NSDQ:ISRG) released its 1st quarter 2016 earnings today, seeing significant gains over last year’s Q1 but a little behind its 2015 Q4.

The Sunnyvale, Calif.-based company beat the street on revenue and earnings per share, and saw shares rise approximately 15% in after hours trading.

Intuitive Surgical reported profits of $136.4 million, or $3.54 per share, on sales of $594.5 million for the 3 months ended March 31. That amounts to a 40.6% bottom-line gain as the companies saw sales grow 11.7% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $4.42, a solid 9¢ above what analysts on Wall Street were looking for. Revenue also beat the Street, though by a more narrow $1.4 million.

Adjusted profits and earnings were more than a quarter up over Q1 2015, clocking in at 26.5% and 23.8% respectively. While Intuitive saw a 3.3% slide in shares today before the Q1 release, shares have lifted approximately 12.5% in after hours trading as of 4:40 p.m. EDT.

“Our 1st quarter strength in total procedure growth and general surgery shows continued expansion of high-quality minimally invasive surgical options around the world. We are pleased that da Vinci technology remains a driver for improved surgical outcomes, building value for hospitals, surgeons and their patients and payers,” CEO Gary Guthart said in a prepared release.

In March, Intuitive Surgical released a study comparing the cost of prostate surgery using its da Vinci robot-assisted surgery device with traditional open surgery.

The study, published in the journal Value in Health, assessed hospital costs, payers’ expenditures and societal expenses related to each procedure. The results showed that the robot-assisted surgery delivered shorter hospital stays, lower complication rates and faster returns to work compared with open procedures.

That meant the costs were $1,094 lower for hospitals and $1,451 lower for payers for the robotic procedure; the societal costs were $1,202 lower, according to the study.

Filed Under: Business/Financial News, Surgical Robotics Tagged With: Intuitive Surgical

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy